-
2024-516772-15-00
1
2025-08-29
Prostate Cancer
-
2024-518276-32-00
4
2025-08-29
Locally advanced and unresectable Stage III non-small cell lung cancer
-
2024-518154-16-00
5
2025-08-27
non-small cell lung cancer
-
2024-515875-36-00
4
2025-08-18
Advanced biliary tract cancer (BTC)
-
2024-519639-40-00
1
2025-08-18
Solid tumors (including Non-Small Cell Lung Cancer (NSCLC), Colorectal
-
2024-516036-94-00
9
2025-08-12
Metastatic castrate resistant prostate cancer - mCRPC
-
2024-520395-99-00
7
2025-08-12
Advanced solid tumors
-
2024-519605-36-00
4
2025-08-08
Melanoma
-
2022-502983-19-00
4
2025-07-31
High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cance
-
2024-512583-57-00
5
2025-07-30
HER2-positive locally advanced or metastatic gastric or gastroesophage
-
2024-515349-41-00
4
2025-07-29
Metastatic Breast Cancer HR+, HER2-
-
2024-520154-38-00
5
2025-07-29
Acute Myeloid Luekemia
-
2024-515311-22-00
3
2025-07-22
low-risk Myelodysplastic Syndromes failing Erythropoiesis Stimulating
-
2023-510356-23-00
1
2025-07-18
Locally advanced or metastatic unresectable colorectal
cancer (CRC)
-
2024-515787-31-00
5
2025-07-18
Patient with early triple-negative breast cancer (TNBC) achieving path
-
2024-515884-69-00
5
2025-07-16
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
-
2024-516162-11-00
5
2025-07-14
Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3CA)-Mutated, Ho
-
2024-516418-39-00
5
2025-07-09
Multiple Myeloma
-
2024-517247-31-00
5
2025-07-07
Newly Diagnosed Higher Risk Myelodysplastic Syndrome
-
2024-519964-42-00
3
2025-07-02
Thrombocythaemia
-
2024-518771-66-00
9
2025-07-01
Hepatoblastoma, Rhabdomyosarcoma
-
2023-504831-42-00
5
2025-06-27
patient with colorectal cancer with hepatic metastasis
-
2024-514596-18-00
9
2025-06-20
Difficult to treat rheumatoid arthritis
-
2024-518469-84-00
4
2025-06-20
Colorectal cancer